Gabor Kos
4 works · 4 citations · h-index 1
Top works
- ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
- Trends in oncology trials termination due to toxicity over a period of 16 years.
- Geographical distribution of industry driven clinical trials performed for leukemia over the last ten years.
- P2.04-008 ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy